Una E Makris1,2, Carlos A Alvarez3, Eric M Mortensen2,4, Ishak A Mansi5,6. 1. Medical Service, VA North Texas Health Care System, 4500 S. Lancaster Road, Dallas, TX, USA. 2. Division of Outcomes and Health Services Research, Departments of Internal Medicine and Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA. 3. Department of Pharmacy Practice, Texas Tech University Health Sciences Center, Dallas, TX, USA. 4. University of Connecticut Medical Center, Farmington, CT, USA. 5. Medical Service, VA North Texas Health Care System, 4500 S. Lancaster Road, Dallas, TX, USA. Ishak.mansi@va.gov. 6. Division of Outcomes and Health Services Research, Departments of Internal Medicine and Clinical Sciences, UT Southwestern Medical Center, Dallas, TX, USA. Ishak.mansi@va.gov.
Abstract
INTRODUCTION: Musculoskeletal conditions, including osteoarthritis (OA), result in tremendous disability and cost. Statins are among the most commonly prescribed medications and their use for primary prevention in many otherwise healthy individuals, including those who are physically active, is increasing. There is conflicting evidence regarding the relationship of statin use and musculoskeletal conditions. Given the rising disability associated with musculoskeletal conditions, understanding predisposing factors, including medication-related exposures, deserves further attention. OBJECTIVES: We examined the association between statin use and the risk of being diagnosed with non-traumatic arthropathies, use-related injury, and undergoing rehabilitation in a cohort with longitudinal follow-up. METHODS: Patients enrolled in a regional military healthcare system between 2003 and 2012 were evaluated in this retrospective cohort study. A propensity score was generated to match statin-users and nonusers using 115 baseline characteristics. Outcomes included ICD-9 diagnoses codes for Agency for Healthcare Research and Quality disease categories of: non-traumatic arthropathies, use-related injury and undergoing rehabilitation. Primary analysis examined the outcomes in statin-users and nonusers after propensity score matching using conditional logistic regression analysis. RESULTS: Initially, 60,455 patients were identified. We propensity score-matched 6728 statin users with 6728 nonusers (52 years of age, ~ 47% women). In the propensity score-matched cohort, non-traumatic arthropathies occurred in 59.8% of statin users and 56.0% of nonusers [odds ratio (OR) 1.17, 95% confidence interval (95% CI) 1.09-1.25] and use related injury occurred in 31.9% of statin users and 29.8% of nonusers (OR 1.11, 95% CI 1.03-1.19). There was no difference between statin users and nonusers undergoing rehabilitation (22.6% among statin users, 21.9% among nonusers, OR 1.04, 95% CI 0.96-1.13). CONCLUSION: Statin use was associated with a significant increased risk of non-traumatic arthropathies and use-related injury. Our results provide additional data that can inform patient and clinician conversations about the benefits and risks of statin use.
INTRODUCTION:Musculoskeletal conditions, including osteoarthritis (OA), result in tremendous disability and cost. Statins are among the most commonly prescribed medications and their use for primary prevention in many otherwise healthy individuals, including those who are physically active, is increasing. There is conflicting evidence regarding the relationship of statin use and musculoskeletal conditions. Given the rising disability associated with musculoskeletal conditions, understanding predisposing factors, including medication-related exposures, deserves further attention. OBJECTIVES: We examined the association between statin use and the risk of being diagnosed with non-traumatic arthropathies, use-related injury, and undergoing rehabilitation in a cohort with longitudinal follow-up. METHODS:Patients enrolled in a regional military healthcare system between 2003 and 2012 were evaluated in this retrospective cohort study. A propensity score was generated to match statin-users and nonusers using 115 baseline characteristics. Outcomes included ICD-9 diagnoses codes for Agency for Healthcare Research and Quality disease categories of: non-traumatic arthropathies, use-related injury and undergoing rehabilitation. Primary analysis examined the outcomes in statin-users and nonusers after propensity score matching using conditional logistic regression analysis. RESULTS: Initially, 60,455 patients were identified. We propensity score-matched 6728 statin users with 6728 nonusers (52 years of age, ~ 47% women). In the propensity score-matched cohort, non-traumatic arthropathies occurred in 59.8% of statin users and 56.0% of nonusers [odds ratio (OR) 1.17, 95% confidence interval (95% CI) 1.09-1.25] and use related injury occurred in 31.9% of statin users and 29.8% of nonusers (OR 1.11, 95% CI 1.03-1.19). There was no difference between statin users and nonusers undergoing rehabilitation (22.6% among statin users, 21.9% among nonusers, OR 1.04, 95% CI 0.96-1.13). CONCLUSION:Statin use was associated with a significant increased risk of non-traumatic arthropathies and use-related injury. Our results provide additional data that can inform patient and clinician conversations about the benefits and risks of statin use.
Authors: Gita Fatemi; Meika A Fang; Paula Breuer; Paul E Cherniak; Angela Gentili; Joseph T Hanlon; Jordan F Karp; Natalia E Morone; Eric Rodriguez; Michelle I Rossi; Kenneth Schmader; Debra K Weiner Journal: Pain Med Date: 2015-08-14 Impact factor: 3.750
Authors: Joseph A Carley; Jordan F Karp; Angela Gentili; Zachary A Marcum; M Carrington Reid; Eric Rodriguez; Michelle I Rossi; Joseph Shega; Stephen Thielke; Debra K Weiner Journal: Pain Med Date: 2015-11-05 Impact factor: 3.750
Authors: Susan E Shoaf; John Ouyang; Olga Sergeyeva; Alvin Estilo; Hui Li; Deborah Leung Journal: Clin J Am Soc Nephrol Date: 2020-04-02 Impact factor: 8.237
Authors: Bahram Mohajer; Ali Guermazi; Philip G Conaghan; Francis Berenbaum; Frank W Roemer; Arya Haj-Mirzaian; Clifton O Bingham; Kamyar Moradi; Xu Cao; Mei Wan; Shadpour Demehri Journal: Eur Radiol Date: 2022-01-19 Impact factor: 7.034